Immunology Based Suicide Prevention Company Campbell Neurosciences Announces Appointment of Public Company Veteran Raymond Oliver as Chairman of the Board

Therapeutic Solutions International Pre-Spin-Off Company Plans to Enter Capital Markets Through Partial Distribution of its Shares to Shareholders of Parent Company

Therapeutic Solutions International, Inc. (TSOI) Pre-Spin-Off Company Plans to Enter Capital Markets Through Partial Distribution of its Shares to Shareholders of Parent Company.

Therapeutic Solutions International pre-spin-off company, Campbell Neurosciences, Inc., announced today appointment of seasoned public company veteran Mr. Raymond Oliver as Chairman of its Board of Directors. This move is part of a larger strategy the suicide prevention company is implementing towards reaching its goal of a public listing.

“Having worked with Mr. Oliver for more than a decade, I am pleased to say that he possesses a very rare combination of talents: He understands the nuances of public markets, he grasps the complexity of science, and he skillfully weaves the two to raise funds and shareholder value for his client companies,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International and former Chairman and Co-Founder of Campbell Neurosciences. “In my opinion no one is more qualified and talented than Mr. Oliver for this position.”

Campbell Neurosciences was recently issued CUSIP number 13436Q109 for its common shares in anticipation of a public listing. Therapeutic Solutions International plans to offer up to 10,000,000 shares of Campbell Neurosciences’ common stock (restricted) it currently holds to its existing shareholders (as of April 30, 2024) in the form of a loyalty dividend ¹ . This elective grant to TSOI shareholders is anticipated to increase the number of Campbell Neurosciences shareholders, thus accelerating the pathway towards public listing.

“We are completing preclinical studies on the CampbellCell, the first-in-class stem cell product for treatment of psychiatric disease, and beginning implementation of the Campbell Score, a blood/saliva test for suicidal propensities,” said Dr. Thomas Ichim, President, and CEO of Campbell Neurosciences. “Given the urgent need for implementation of these technologies, we are eager to work with Mr. Oliver who has an excellent track record of not only raising funds for public companies, but doing so in a manner that is beneficial and not detrimental in the long-term to shareholders.”

Investor and entrepreneur, Mr. Oliver has assisted companies to get in position for financing and acceleration. Mr. Oliver has been instrumental in sourcing capital for both private and public companies having spent 35 years in the financial markets. Mr. Oliver spent his first 10 years as a Series 7 and 63 licensed retail stockbroker managing all levels of equities markets. Mr. Oliver has spent many years working internally as an executive of multiple public companies. Mr. Oliver’s introductions have resulted in millions of dollars in equity financing in both public and private companies. His capital market specialties include introductions to retail brokers, institutions, money managers, small cap funds, analyst, and others, many having been in his network for over 30 years.

“I am humbled and honored to continue the work of Mr. Timothy Dixon as Chairman of Campbell Neurosciences. Under the guidance of Mr. Dixon, the Company successfully demonstrated efficacy of the Campbell Score in predicting suicidal ideations ² , recruited a top-notch advisory board including a founder of a 30-billion-dollar company ³ , and published in collaboration with Stanford University nutraceutical modulation of depression associated cytokines ⁴ ,” said Raymond Oliver. “I look forward to working with Dr. Ichim who has taken his stem cell company Medistem, from an 8 cent share price to sale at $1.35 to the NYSE traded company Intrexon and took two companies to a NASDAQ listing. Based on his track record of business successes, as well as his history of innovations (having over 400 published and issued patents), I believe we will make significant progress in tending to a segment of society that traditionally has been overlooked by the drug development industry.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com .

1 https://www.otcmarkets.com/filing/html?id=17511475&guid=40Q-kqzm3kn4B3h
2 https://classic.clinicaltrials.gov/ct2/show/NCT04606875
3 https://www.prnewswire.com/news-releases/therapeutic-solutions-international-announces-titan-of-industry-dr-peter-farrell-joins-advisory-board-of-its-suicide-prevention-spin-off-campbell-neurosciences-301359622.html
4 https://www.businesswire.com/news/home/20231127794359/en/Therapeutic-Solutions-International-and-Campbell-Neurosciences-Publish-on-Nutritional-Modulation-of-the-Indolamine-23-Dioxygenase-Pathway-as-a-Non-Toxic-Means-of-Addressing-Depression